Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/201067
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFernández Velasco, José I.-
dc.contributor.authorMonreal, Enric-
dc.contributor.authorKuhle, Jens-
dc.contributor.authorMeca Lallana, Virginia-
dc.contributor.authorMeca Lallana, José E.-
dc.contributor.authorIzquierdo, Guillermo-
dc.contributor.authorOreja Guevara, Celia-
dc.contributor.authorGascón Gimenez, Francisco-
dc.contributor.authorSainz de la Maza, Susana-
dc.contributor.authorWalo Delgado, Paulette E.-
dc.contributor.authorLapuente Suanzes, Paloma-
dc.contributor.authorMaceski, Aleksandra-
dc.contributor.authorRodriguez Martín, Eulalia-
dc.contributor.authorRoldán, Ernesto-
dc.contributor.authorVillarrubia, Noelia-
dc.contributor.authorSaiz Hinarejos, Albert-
dc.contributor.authorBlanco, Yolanda-
dc.contributor.authorDiaz Pérez, Carolina-
dc.contributor.authorValero López, Gabriel-
dc.contributor.authorDíaz Díaz, Judit-
dc.contributor.authorAladro, Yolanda-
dc.contributor.authorBrieva, Luis-
dc.contributor.authorIñíguez, Cristina-
dc.contributor.authorGonzález Suárez, Inés-
dc.contributor.authorRodríguez de Antonio, Luis A.-
dc.contributor.authorGarcía Domínguez, José M.-
dc.contributor.authorSabin, Julia-
dc.contributor.authorLlufriu Duran, Sara-
dc.contributor.authorMasjuan, Jaime-
dc.contributor.authorCosta Frossard, Lucienne-
dc.contributor.authorVillar, Luisa M.-
dc.date.accessioned2023-07-24T12:25:49Z-
dc.date.available2023-07-24T12:25:49Z-
dc.date.issued2022-03-21-
dc.identifier.issn1664-3224-
dc.identifier.urihttp://hdl.handle.net/2445/201067-
dc.description.abstractTo ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.Copyright © 2022 Fernández-Velasco, Monreal, Kuhle, Meca-Lallana, Meca-Lallana, Izquierdo, Oreja-Guevara, Gascón-Giménez, Sainz de la Maza, Walo-Delgado, Lapuente-Suanzes, Maceski, Rodríguez-Martín, Roldán, Villarrubia, Saiz, Blanco, Diaz-Pérez, Valero-López, Diaz-Diaz, Aladro, Brieva, Íñiguez, González-Suárez, Rodríguez de Antonio, García-Domínguez, Sabin, Llufriu, Masjuan, Costa-Frossard and Villar.-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.842354-
dc.relation.ispartofFrontiers In Immunology, 2022, vol. 13-
dc.relation.urihttps://doi.org/10.3389/fimmu.2022.842354-
dc.rightscc by (c) Fernández Velasco, José I. et al, 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)-
dc.subject.classificationEsclerosi múltiple-
dc.subject.classificationImatges per ressonància magnètica-
dc.subject.otherMultiple sclerosis-
dc.subject.otherMagnetic resonance imaging-
dc.titleBaseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2023-07-19T09:42:57Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.idimarina9306915-
dc.identifier.pmid35386690-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)



This item is licensed under a Creative Commons License Creative Commons